Editorial Policy

Independence

BioIntel is editorially independent. We aim to publish clear, decision-useful analysis for biotech founders, investors, and operators without pay-to-play coverage.

What we publish

We cover biotech and biopharma, AI in drug discovery, healthcare technology, financing, M&A, regulation, and operator-level strategy. Our focus is on explaining what changed, why it matters, and what to watch next.

Standards for accuracy and sourcing

• We prioritize primary sources when available, including regulatory filings, peer-reviewed research, official press releases, and direct statements.
• We use secondary sources to add context, not to replace primary evidence.
• We differentiate reporting from commentary and label opinion where appropriate.

Editorial judgment

BioIntel may summarize complex topics and make reasonable analytical judgments. We strive to be explicit about assumptions and uncertainty.

Corrections

If we publish an error, we will correct it as quickly as practical. If you believe something is incorrect, email us with the URL and a brief explanation.

Conflicts of interest

We avoid conflicts of interest that could compromise credibility. If content is ever sponsored or includes a material relationship, we will disclose it clearly.

Reader feedback

We welcome feedback, corrections, and story suggestions. The best way to reach us is by email.